Bronchi-Shield III - Bordetella + Adenovirus + Parainfluenza Modified live + avirulent live Bordetella bronchiseptica. Bronchi-Shield III is for protection against canine adenovirus type 2, parainfluenza and bordetella bronchiseptica. Bronchi-Shield III is for dogs 8 weeks of age or older. Give intranasally. Instill 0.5 ml into each nostril. Annual revaccination is recommended. A very small percentage of animals may show sneezing, coughing, or nasal discharge following vaccination. These signs are usually transient. Requires mixing. Applicator tips are enclosed. Order syringes separately.
For vaccination of healthy dogs and puppies eight weeks of age or older as an aid in prevention disease caused by Bordetella bronchiseptica, canine parainfluenza virus and canine adenovirus type 2.
Preparation of the Vaccaine:
Rehydrate with the accompanying sterile diluent. Shake well and draw back into the syringe the required amount. Remove needle from syringe and attach enclosed applicator tip. Use immediately.
Administration and Dosage
Instill 0.5 ml of rehydrated vaccine into each nostril using a syringe with applicator tip. Annual revaccination is recommended.
This product is designed for INTRANASAL USE ONLY. DO NOT VACCINATE DOGS PARENTERALLY. A very small percentage of animals may show sneezing, coughing or nasal discharge following vaccination. These signs are usually transient. Store in the dark at 2° to 7°C (35° to 45°F). AVOID FREEZING. Shake well after rehydration. Burn container and all unused contents. In case of anaphylactoid reaction, administer epinephrine. FOR INTRANASAL USE ONLY DO NOT VACCINATE DOGS PARENTERALLY.
All vaccines are shipped overnight. A $29.95 flat rate fee is charged for all orders containing vaccines. Someone should be present to sign for and receive the vaccine order when it ships to you. For more shipping info click here.
Bronchi-Shield® ORAL is an avirulent Bordetella bronchiseptica vaccine licensed to be administered orally.
The Study Structure
Eight-week-old puppies received a single dose of Bronchi-Shield® ORAL in the buccal cavity.
Puppies were challenge through aerosol transmission of a virulent strain of Bordetella bronchiseptica five weeks later.
Puppies were observed for two weeks for clinical signs of infectious canine tracheobronchitis (ITB).
All 15 non-vaccinated control dogs developed ITB and coughed for an average of six days.*
Bronchi-Shield ORAL provided 93 percent efficacy. Only one of 14 vaccinates developed ITB, and this dog coughed for two days.
* The clinical case definition for ITB was defined as a dog coughed for at least two days. Control dogs coughed an average of six days, whereas one vaccinate coughed for two days.
Convenience, Safety and Efficacy1
A new combination of convenience and efficacy is here.
Bronchi-Shield® ORAL shows excellent protection against challenge by primary pathogen causing Canine Infectious Respiratory Disease (CIRD).
Offers safety demonstrated in Field trial2
Is covered by the Boehringer Ingelheim Vetmedica, Inc. Vaccine Assurance Program.
1Hess, et al., Evaluation of Efficacy if Oral Administration of Bordetella Bronchiseptica Intranasal Vaccine When Used to Project Puppies from Tracheobronchitis Due to B. bronchiseptica Infection, Intern J Appl Res Vet Med., Vol 9, No 3, 2011, pgs 300-305
2Data on file.
*The clinical case definition for ITB was defined as a dog that coughed dor at least two days. Control dogs coughed an average of six days, whereas one vaccinate coughed for two days.